Companies

SELLAS Life Sciences Group, Inc. (SLS) SEC filings

CIK 0001390478 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2025FY2024FY2023FY2022
Revenue (USD)07.6 M
Net income (USD)-41.3 M-20.7 M
Diluted EPS (USD/shares)-0.25-1.34-2.13

Latest filings

FiledFormDescriptionPeriod
2026-08-118-K8-K items 2.02,9.012026-08-11
2026-08-1110-Q10-Q2026-06-30
2026-08-07SCHEDULE 13GSCHEDULE 13G
2026-07-31SCHEDULE 13GSCHEDULE 13G
2026-07-278-KFORM 8-K items 2.02,8.01,9.012026-07-24
2026-06-258-KFORM 8-K items 5.02,9.012026-06-24
2026-06-188-KFORM 8-K items 5.072026-06-16
2026-06-184OWNERSHIP DOCUMENT2026-06-16
2026-06-16S-8FORM S-8
2026-06-028-KFORM 8-K items 8.01,9.012026-06-02
2026-05-128-K8-K items 2.02,9.012026-05-12
2026-05-1210-Q10-Q2026-03-31
2026-04-24SCHEDULE 13G/ASCHEDULE 13G/A
2026-04-23ARSARS2025-12-31
2026-04-23DEFA14ADEFA14A
2026-04-23DEF 14AFORM- DEF 14A2026-06-16
2026-03-27SCHEDULE 13G/ASCHEDULE 13G/A
2026-03-20S-3ASRS-3ASR
2026-03-198-K8-K items 2.02,9.012026-03-19
2026-03-1910-K10-K2025-12-31
2026-03-118-KFORM 8-K items 8.01,9.012026-03-11
2026-02-17SCHEDULE 13G/ASCHEDULE 13G/A
2026-01-30SCHEDULE 13G/ASCHEDULE 13G/A
2026-01-094OWNERSHIP DOCUMENT2026-01-07
2026-01-094OWNERSHIP DOCUMENT2026-01-07

Forms on file (last 1,000): 8-K 265, 4 251, 10-Q 47, CORRESP 40, 3 31, 424B5 30, UPLOAD 28, EFFECT 25. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=SLS (0.002 USD), /gw/filings/filings?ticker=SLS&form=8-K, /gw/filings/facts?ticker=SLS&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange